Worldwide chairwoman Sandi Peterson told Leerink’s Danielle Antalffy that the company has faith in its ability to “compete effectively” in cardiology with just two key operations in place, “which would imply no imminent acquisition in this space is likely,” according to an investors note sent out this morning.
“Peterson remains confident that JNJ can remain competitive within cardiology with just an electrophysiology (EP) and neurovascular portfolio, which would imply that JNJ has no plans to acquire a full-service cardiology company at this time,” Antalffy wrote.
Still, that doesn’t rule out some M&A in the future for the world’s second-largest medical device business, she wrote.
“Though acquisitions are seemingly off the table right now, we still believe there is future potential in the years to come for JNJ to be acquisitive in order to build scale within cardiology,” Antalffy wrote.
The news comes amid a flurry of consolidation in medtech including some participation from J&J, which in recent weeks agreed to roll its TearScience acquisition together with its Abbott Medical Optics buy and rolled out a new neurovascular business, dubbed Cerenovus, to encompass its recent Pulsar Vascular and Neuravi pickups plus its existing Codman Neuro portfolio.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.